Donato et al. have demonstrated that Lyn and Hck, were upregulated in imatinib mesylate resistant cell line and in specimens of advanced CML and ALL from patients who relapsed to imatinib mesylate [149, 156]. This evidence concerns the gene LYN and acute lymphoblastic leukemia.